The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption
Abstract
Organic anion transporting polypeptide (OATP) family transporters accept a number of drugs and are increasingly being recognized as important factors in governing drug and metabolite pharmacokinetics. OATP1B1 and OATP1B3 play an important role in hepatic drug uptake while OATP2B1 and OATP1A2 might be key players in intestinal absorption and transport across blood–brain barrier of drugs, respectively. To understand the importance of OATPs in the hepatic clearance of drugs, the rate‐determining process for elimination should be considered; for some drugs, hepatic uptake clearance rather than metabolic intrinsic clearance is the more important determinant of hepatic clearances. The importance of the unbound concentration ratio (liver/blood),Kp,uu, of drugs, which is partly governed by OATPs, is exemplified in interpreting the difference in the IC 50 of statins between the hepatocyte and microsome systems for the inhibition of HMG‐CoA reductase activity. The intrinsic activity and/or expression level of OATPs are affected by genetic polymorphisms and drug–drug interactions. Their effects on the elimination rate or intestinal absorption rate of drugs may sometimes depend on the substrate drug. This is partly because of the different contribution of OATP isoforms to clearance or intestinal absorption. When the contribution of the OATP‐mediated pathway is substantial, the pharmacokinetics of substrate drugs should be greatly affected. This review describes the estimation of the contribution of OATP1B1 to the total hepatic uptake of drugs from the data of fold‐increases in the plasma concentration of substrate drugs by the genetic polymorphism of this transporter. To understand the importance of the OATP family transporters, modeling and simulation with a physiologically based pharmacokinetic model are helpful. Copyright © 2012 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationMammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00169-2 · Cited by 1,386
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.027 · Cited by 1,231
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors
Uchida, Y., Ohtsuki, S., Katsukura, Y., Ikeda, C., Suzuki, T., Kamiie, J., & Terasaki, T. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07208.x · Cited by 881
The superfamily of organic anion transporting polypeptides
Hagenbuch, B., & Meier, P. J. (2003) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(02)00633-8 · Cited by 861
Pang, K. S., & Rowland, M. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059688 · Cited by 797
Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D., & Thummel, K. E. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37149-6 · Cited by 789
Clearance concepts in pharmacokinetics
Rowland, M., Benet, L. Z., & Graham, G. G. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059626 · Cited by 649
Tamai, I., Nezu, J.-I., Uchino, H., Sai, Y., Oku, A., Shimane, M., & Tsuji, A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2922 · Cited by 642
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641
Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 633
Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 626
König, J., Cui, Y., Nies, A. T., & Keppler, D. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.1.g156 · Cited by 620
Dresser, G. K., Bailey, D. G., Leake, B. F., Schwarz, U. I., Dawson, P. A., Freeman, D. J., & Kim, R. B. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121152 · Cited by 606
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 576
Self-citationIdentification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1
Abe, T., Kakyo, M., Tokui, T., Nakagomi, R., Nishio, T., Nakai, D., Nomura, H., Unno, M., Suzuki, M., Naitoh, T., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17159 · Cited by 543
The SLC22 drug transporter family
Koepsell, H., & Endou, H. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1089-9 · Cited by 525
Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting Polypeptide
König, J., Cui, Y., Nies, A. T., & Keppler, D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001448200 · Cited by 522
Hepatic Uptake of Bilirubin and Its Conjugates by the Human Organic Anion Transporter SLC21A6
Cui, Y., König, J., Leier, I., Buchholz, U., & Keppler, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004968200 · Cited by 515
Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 512
Self-citationNishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
Transporters as a determinant of drug clearance and tissue distribution
Shitara, Y., Horie, T., & Sugiyama, Y. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.12.003 · Cited by 496
Self-citationImpact of Drug Transporter Studies on Drug Discovery and Development
Mizuno, N., Niwa, T., Yotsumoto, Y., & Sugiyama, Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.1 · Cited by 490
Self-citationRitonavir: Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents
Hsu, A., Granneman, G. R., & Bertz, R. J. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835040-00002 · Cited by 483
LEE, E., RYAN, S., BIRMINGHAM, B., ZALIKOWSKI, J., MARCH, R., AMBROSE, H., MOORE, R., LEE, C., CHEN, Y., & SCHNECK, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.013 · Cited by 480
Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479
Self-citationKamiie, J., Ohtsuki, S., Iwase, R., Ohmine, K., Katsukura, Y., Yanai, K., Sekine, Y., Uchida, Y., Ito, S., & Terasaki, T. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9532-4 · Cited by 478
Ezetimibe: A Review of its Metabolism, Pharmacokinetics and Drug Interactions
Kosoglou, T., Statkevich, P., Johnson-Levonas, A. O., Paolini, J. F., Bergman, A. J., & Alton, K. B. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544050-00002 · Cited by 476
Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068056 · Cited by 443
Self-citationOhtsuki, S., Schaefer, O., Kawakami, H., Inoue, T., Liehner, S., Saito, A., Ishiguro, N., Kishimoto, W., Ludwig-Schwellinger, E., Ebner, T., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042259 · Cited by 434
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100220 · Cited by 432
Niemi, M., Schaeffeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., Backman, J. T., Kerb, R., Schwab, M., Neuvonen, P. J., et al. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114750.08559.32 · Cited by 418
McTaggart, F., Buckett, L., Davidson, R., Holdgate, G., McCormick, A., Schneck, D., Smith, G., & Warwick, M. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01454-0 · Cited by 413
Gao, B., Hagenbuch, B., Kullak-Ublick, G. A., Benke, D., Aguzzi, A., & Meier, P. J. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39041-x · Cited by 412
Shitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407
Self-citationIntestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans
Glaeser, H., Bailey, D. G., Dresser, G. K., Gregor, J. C., Schwarz, U. I., McGrath, J. S., Jolicoeur, E., Lee, W., Leake, B. F., Tirona, R. G., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100056 · Cited by 407
Huang, S., Strong, J. M., Zhang, L., Reynolds, K. S., Nallani, S., Temple, R., Abraham, S., Habet, S. A., Baweja, R. K., Burckart, G. J., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007312153 · Cited by 396
Carrier-Mediated Intestinal Transport of Drugs
Tsuji, A., & Tamai, I. (1996) · Pharmaceutical Research · doi:10.1023/a:1016086003070 · Cited by 392
Dawson, P. A., Hubbert, M., Haywood, J., Craddock, A. L., Zerangue, N., Christian, W. V., & Ballatori, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412752200 · Cited by 381
Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M., & Chiba, K. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000170913.73780.5f · Cited by 379
Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2)
Lee, W., Glaeser, H., Smith, L. H., Roberts, R. L., Moeckel, G. W., Gervasini, G., Leake, B. F., & Kim, R. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411092200 · Cited by 365
Meier, P. J., Eckhardt, U., Schroeder, A., Hagenbuch, B., & Stieger, B. (1997) · Hepatology · doi:10.1002/hep.510260641 · Cited by 362
Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin
Kitamura, S., Maeda, K., Wang, Y., & Sugiyama, Y. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021410 · Cited by 361
Self-citationFunctional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human
Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060194 · Cited by 351
Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y., & Sugiyama, Y. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146647 · Cited by 351
Self-citationAbe, T., Unno, M., Onogawa, T., Tokui, T., Kondo, T. N., Nakagomi, R., Adachi, H., Fujiwara, K., Okabe, M., Suzuki, T., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.24804 · Cited by 345
Shitara, Y., Itoh, T., Sato, H., Li, A. P., & Sugiyama, Y. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041921 · Cited by 340
Self-citationLau, Y. Y., Huang, Y., Frassetto, L., & Benet, L. Z. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100038 · Cited by 327
Nozawa, T., Nakajima, M., Tamai, I., Noda, K., Nezu, J.-I., Sai, Y., Tsuji, A., & Yokoi, T. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.2.804 · Cited by 318
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009290 · Cited by 302
Self-citationEvidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
Mwinyi, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.016 · Cited by 293
Noé, J., Portmann, R., Brun, M.-E., & Funk, C. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012930 · Cited by 291
Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist
Dingemanse, J., & van Giersbergen, P. L. M. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443150-00003 · Cited by 272
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
NIEMI, M., PASANEN, M., & NEUVONEN, P. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.06.010 · Cited by 250
Ito, K., Uchida, Y., Ohtsuki, S., Aizawa, S., Kawakami, H., Katsukura, Y., Kamiie, J., & Terasaki, T. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22487 · Cited by 230
Rao, A., Haywood, J., Craddock, A. L., Belinsky, M. G., Kruh, G. D., & Dawson, P. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712328105 · Cited by 225
CITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B
Satoh, H., Yamashita, F., Tsujimoto, M., Murakami, H., Koyabu, N., Ohtani, H., & Sawada, Y. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002337 · Cited by 225
Recent Advances in Carrier-mediated Hepatic Uptake and Biliary Excretion of Xenobiotics
Yamazaki, M., Suzuki, H., & Sugiyama, Y. (1996) · Pharmaceutical Research · doi:10.1023/a:1016077517241 · Cited by 221
Self-citationRole of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor
Polli, J. W., Jarrett, J. L., Studenberg, S. D., Humphreys, J. E., Dennis, S. W., Brouwer, K. R., & Woolley, J. L. (1999) · Pharmaceutical Research · doi:10.1023/a:1018941328702 · Cited by 218
Nakai, D., Nakagomi, R., Furuta, Y., Tokui, T., Abe, T., Ikeda, T., & Nishimura, K. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29609-9 · Cited by 217
Ieiri, I., Higuchi, S., & Sugiyama, Y. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902976854 · Cited by 212
Self-citationAltered Hepatic Blood Flow and Drug Disposition1
Nies, A. S., Shand, D. G., & Wilkinson, G. R. (1976) · Clinical Pharmacokinetics · doi:10.2165/00003088-197601020-00005 · Cited by 212
Tamai, I., Nozawa, T., Koshida, M., Nezu, J.-I., Sai, Y., & Tsuji, A. (2001) · Pharmaceutical Research · doi:10.1023/a:1013077609227 · Cited by 211
Maeda, K., Ikeda, Y., Fujita, T., Yoshida, K., Azuma, Y., Haruyama, Y., Yamane, N., Kumagai, Y., & Sugiyama, Y. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.142 · Cited by 211
Self-citationFlesch, G., Müller, P., & Lloyd, P. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050259 · Cited by 203
Intestinal efflux transporters and drug absorption
Murakami, T., & Takano, M. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.7.923 · Cited by 201
Interactions of Green Tea Catechins with Organic Anion-Transporting Polypeptides
Roth, M., Timmermann, B. N., & Hagenbuch, B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.036640 · Cited by 201
MAEDA, K., IEIRI, I., YASUDA, K., FUJINO, A., FUJIWARA, H., OTSUBO, K., HIRANO, M., WATANABE, T., KITAMURA, Y., & KUSUHARA, H. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.011 · Cited by 200
Self-citationHallifax, D., Foster, J. A., & Houston, J. B. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0218-3 · Cited by 195
Watanabe, T., Kusuhara, H., Maeda, K., Kanamaru, H., Saito, Y., Hu, Z., & Sugiyama, Y. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.030254 · Cited by 194
Self-citationMougey, E. B., Feng, H., Castro, M., Irvin, C. G., & Lima, J. J. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32831bd98c · Cited by 190
A regulatory viewpoint on transporter-based drug interactions
Zhang, L., Zhang, Y. (. )., Strong, J. M., Reynolds, K. S., & Huang, S.-M. (2008) · Xenobiotica · doi:10.1080/00498250802017715 · Cited by 188
Shimizu, M., Fuse, K., Okudaira, K., Nishigaki, R., Maeda, K., Kusuhara, H., & Sugiyama, Y. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004622 · Cited by 183
Self-citationImanaga, J., Kotegawa, T., Imai, H., Tsutsumi, K., Yoshizato, T., Ohyama, T., Shirasaka, Y., Tamai, I., Tateishi, T., & Ohashi, K. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834300cc · Cited by 181
Ishiguro, N., Maeda, K., Kishimoto, W., Saito, A., Harada, A., Ebner, T., Roth, W., Igarashi, T., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.009175 · Cited by 178
Self-citationEffect of () variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers
CHUNG, J., CHO, J., YU, K., KIM, J., OH, D., JUNG, H., LIM, K., MOON, K., SHIN, S., & JANG, I. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.003 · Cited by 170
Letrent, S. P., Pollack, G. M., Brouwer, K. R., & Brouwer, K. L. R. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)11822-3 · Cited by 169
Maeda, K., & Sugiyama, Y. (2008) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.23.223 · Cited by 165
Self-citationPicard, N., Yee, S. W., Woillard, J.-B., Lebranchu, Y., Le Meur, Y., Giacomini, K. M., & Marquet, P. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.205 · Cited by 165
Ieiri, I., Suwannakul, S., Maeda, K., Uchimaru, H., Hashimoto, K., Kimura, M., Fujino, H., Hirano, M., Kusuhara, H., Irie, S., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100190 · Cited by 164
Self-citationYoshida, K. J., Maeda, K., & Sugiyama, Y. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.351 · Cited by 156
Self-citationScientific Perspectives on Drug Transporters and Their Role in Drug Interactions
Zhang, L., Strong, J. M., Qiu, W., Lesko, L. J., & Huang, S. M. (2006) · Molecular Pharmaceutics · doi:10.1021/mp050095h · Cited by 153
Yamazaki, M., Suzuki, H., Hanano, M., Tokui, T., Komai, T., & Sugiyama, Y. (1993) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1993.264.1.g36 · Cited by 152
Self-citationGrapefruit juice ingestion significantly reduces talinolol bioavailability
Schwarz, U. I., SEEMANN, D., Oertel, R., Miehlke, S., Kuhlisch, E., Fromm, M. F., KIM, R., Bailey, D. G., & Kirch, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.11.111 · Cited by 149
Ose, A., Kusuhara, H., Endo, C., Tohyama, K., Miyajima, M., Kitamura, S., & Sugiyama, Y. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029454 · Cited by 148
Self-citationGertz, M., Cartwright, C. M., Hobbs, M. J., Kenworthy, K. E., Rowland, M., Houston, J. B., & Galetin, A. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0918-y · Cited by 148
Iwai, M., Suzuki, H., Ieiri, I., Otsubo, K., & Sugiyama, Y. (2004) · Pharmacogenetics · doi:10.1097/00008571-200411000-00006 · Cited by 147
Self-citationUse of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo
Soars, M. G., Grime, K., Sproston, J. L., Webborn, P. J. H., & Riley, R. J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014464 · Cited by 145
Yamada, A., Maeda, K., Kamiyama, E., Sugiyama, D., Kondo, T., Shiroyanagi, Y., Nakazawa, H., Okano, T., Adachi, M., Schuetz, J. D., et al. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017459 · Cited by 143
Self-citationItraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol
Lilja, J. J., Backman, J. T., Laitila, J., Luurila, H., & Neuvonen, P. J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.26 · Cited by 142
Niemi, M., Kivistö, K. T., Hofmann, U., Schwab, M. G., Eichelbaum, M. F., & Fromm, M. F. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02354.x · Cited by 135
Amundsen, R., Christensen, H., Zabihyan, B., & Åsberg, A. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032268 · Cited by 135
Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel‐induced leukopenia
Kiyotani, K., Mushiroda, T., Kubo, M., Zembutsu, H., Sugiyama, Y., & Nakamura, Y. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00765.x · Cited by 134
Self-citationInfluence of OATP1B1 Genotype on the Pharmacokinetics of Rosuvastatin in Koreans
Choi, J., Lee, M., Cho, J.-Y., Lee, J.-E., Kim, K. H., & Park, K. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100267 · Cited by 131
Clinical Importance of OATP1B1 and OATP1B3 in DrugDrug Interactions
Shitara, Y. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-rv-094 · Cited by 130
Self-citationIntestinal First-Pass Metabolism of CYP3A4 Substrates
Kato, M. (2008) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.23.87 · Cited by 130
EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN
Sun, H. L., Huang, Y., Frassetto, L. A., & Benet, L. Z. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000521 · Cited by 128
Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs
Yabe, Y., Galetin, A., & Houston, J. B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040477 · Cited by 126
Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol
Spahn-Langguth, H., & Langguth, P. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00191-3 · Cited by 125
Cui, D., Booth-Genthe, C. L., Carlini, E., Carr, B., & Schrag, M. L. (2004) · PubMed · doi:10.1124/dmd.32.11 · Cited by 124
Hagenbuch, B., Scharschmidt, B. F., & Meier, P. J. (1996) · Biochemical Journal · doi:10.1042/bj3160901 · Cited by 122
Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans
Carlile, D. J., Hakooz, N., Bayliss, M. K., & Houston, J. B. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00935.x · Cited by 118
Karlgren, M., Ahlin, G., Bergström, C. A. S., Svensson, R., Palm, J. E., & Artursson, P. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0564-9 · Cited by 118
Lappin, G., Shishikura, Y., Jochemsen, R., Weaver, R. J., Gesson, C., Houston, B., Oosterhuis, B., Bjerrum, O. J., Rowland, M., & Garner, R. C. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.03.009 · Cited by 117
Ménochet, K., Kenworthy, K. E., Houston, J. B., & Galetin, A. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.046193 · Cited by 115
Nakanishi, T., & Tamai, I. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rv-099 · Cited by 112
Igel, M., ARNOLD, K., Niemi, M., Hofmann, U., Schwab, M. G., Lütjohann, D., VONBERGMANN, K., Eichelbaum, M. F., & Kivistö, K. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.010 · Cited by 108
Ieiri, I., Doi, Y., Maeda, K., Sasaki, T., Kimura, M., Hirota, T., Chiyoda, T., Miyagawa, M., Irie, S., Iwasaki, K., et al. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011408612 · Cited by 107
Self-citationKindla, J., Müller, F., Mieth, M., Fromm, M. F., & König, J. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037622 · Cited by 106
Watanabe, T., Kusuhara, H., Watanabe, T., Debori, Y., Maeda, K., Kondo, T., Nakayama, H., Horita, S., Ogilvie, B. W., Parkinson, A., et al. (2011) · Drug Metabolism And Disposition · doi:10.1124/dmd.110.036129 · Cited by 105
Self-citationTapaninen, T., Neuvonen, P. J., & Niemi, M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.101 · Cited by 104
Li, N., Palandra, J., Nemirovskiy, O. V., & Lai, Y. (2009) · Analytical Chemistry · doi:10.1021/ac8024009 · Cited by 101
Nakagomi, R., Nakai, D., Kawai, K., Yoshigae, Y., Tokui, T., Abe, T., & Ikeda, T. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008888 · Cited by 100
Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin
Nezasa, K.-I., Higaki, K., Takeuchi, M., Nakano, M., & Koike, M. (2003) · Xenobiotica · doi:10.1080/0049825031000066259 · Cited by 98
Li, N., Zhang, Y., Hua, F., & Lai, Y. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023234 · Cited by 98
Zhao, P., Vieira, M. D. L. T., Grillo, J. A., Song, P., Wu, T., Zheng, J., Arya, V., Berglund, E. G., Atkinson, A. J., Sugiyama, Y., et al. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011415528 · Cited by 98
Self-citationStringer, R. A., Nicklin, P. L., & Houston, J. B. (2008) · Xenobiotica · doi:10.1080/00498250802446286 · Cited by 89
Chang, C. K., Pang, K. S., Swaan, P. W., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.082370 · Cited by 88
Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism
He, Y., Zhang, W., Chen, Y., Guo, D., Tu, J., Xu, L., Tan, Z., Chen, B., Li, Z., Zhou, G., et al. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.04.003 · Cited by 88
Shitara, Y., Takeuchi, K., Nagamatsu, Y., Wada, S., Sugiyama, Y., & Horie, T. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rg-096 · Cited by 87
Self-citationLam, J. L., & Benet, L. Z. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.11.1311 · Cited by 85
Kalliokoski, A., Backman, J. T., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.74 · Cited by 84
Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data
Poirier, A., Cascais, A., Funk, C., & Lavé, T. (2009) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-009-9139-3 · Cited by 81
Lin, J., Sugiyama, Y., Awazu, S., & Hanano, M. (1982) · Journal of pharmacokinetics and biopharmaceutics · doi:10.1007/bf01062545 · Cited by 79
Self-citationKouzuki, H., Suzuki, H., Ito, K., Ohashi, R., & Sugiyama, Y. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37686-4 · Cited by 78
Self-citationWatanabe, T., Maeda, K., Kondo, T., Nakayama, H., Horita, S., Kusuhara, H., & Sugiyama, Y. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.026062 · Cited by 72
Self-citationEffect of Citrus Juice andSLCO2B1Genotype on the Pharmacokinetics of Montelukast
Mougey, E. B., Lang, J. E., Wen, X., & Lima, J. J. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010374472 · Cited by 68
Tachibana, T., Kato, M., Watanabe, T., Mitsui, T., & Sugiyama, Y. (2009) · Xenobiotica · doi:10.1080/00498250902846252 · Cited by 67
Self-citationSoars, M. G., Webborn, P. J. H., & Riley, R. J. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800246x · Cited by 66
Parker, A. J., & Houston, J. B. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020917 · Cited by 64
Shitara, Y., Nagamatsu, Y., Wada, S., Sugiyama, Y., & Horie, T. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.025544 · Cited by 62
Self-citationYamada, A., Maeda, K., Ishiguro, N., Tsuda, Y., Igarashi, T., Ebner, T., Roth, W., Ikushiro, S., & Sugiyama, Y. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283482502 · Cited by 61
Self-citationInfluence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers
Akamine, Y., Miura, M., Sunagawa, S., Kagaya, H., Yasui‐Furukori, N., & Uno, T. (2010) · Xenobiotica · doi:10.3109/00498254.2010.515318 · Cited by 60
Predicting Drug – Drug Interactions Involving the Inhibition of Intestinal CYP3A4 and P-Glycoprotein
Tachibana, T., Kato, M., Takano, J., & Sugiyama, Y. (2010) · Current Drug Metabolism · doi:10.2174/138920010794328922 · Cited by 59
Self-citationUeda, K., Kato, Y., Komatsu, K., & Sugiyama, Y. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29630-0 · Cited by 58
Self-citationBrown, H. S., Chadwick, A., & Houston, J. B. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017095 · Cited by 55
Kouzuki, H., Suzuki, H., Ito, K., Ohashi, R., & Sugiyama, Y. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37999-6 · Cited by 50
Self-citationZhang, Y., Li, N., Brown, P. W., Ozer, J. S., & Lai, Y. (2011) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.5026 · Cited by 47
Sugiyama, D., Kusuhara, H., Shitara, Y., Abe, T., & Sugiyama, Y. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.2.220 · Cited by 46
Self-citationEffects of grapefruit juice on the pharmacokinetics of acebutolol
Lilja, J. J., Raaska, K., & Neuvonen, P. J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02489.x · Cited by 45
Kusama, M., Maeda, K., Chiba, K., Aoyama, A., & Sugiyama, Y. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9781-2 · Cited by 45
Self-citationRawden, H. C., Carlile, D. J., Tindall, A. J., Hallifax, D., Galetin, A., Ito, K., & Houston, J. B. (2005) · Xenobiotica · doi:10.1080/00498250500162870 · Cited by 45
Werner, D., Werner, U., Meybaum, A., Schmidt, B., Umbreen, S., Grosch, A., Lestin, H., Graf, B., Zolk, O., & Fromm, M. F. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00003 · Cited by 41
Vormfelde, S. V., Toliat, M., Schirmer, M., Meineke, I., Nürnberg, P., & Brockmöller, J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100404 · Cited by 41
Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism
Suwannakul, S., Ieiri, I., Kimura, M., Kawabata, K., Kusuhara, H., Hirota, T., Irie, S., Sugiyama, Y., & Higuchi, S. (2008) · Journal of Human Genetics · doi:10.1007/s10038-008-0324-9 · Cited by 39
Self-citationIn Silico Classification of Major Clearance Pathways of Drugs with Their Physiochemical Parameters
Kusama, M., Toshimoto, K., Maeda, K., Hirai, Y., Imai, S., Chiba, K., Akiyama, Y., & Sugiyama, Y. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032789 · Cited by 39
Self-citationBrown, H. S., Wilby, A. J., Alder, J. E., & Houston, J. B. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035824 · Cited by 35
Kitamura, Y., Kusuhara, H., & Sugiyama, Y. (2010) · Pharmaceutical Research · doi:10.1007/s11095-009-0047-4 · Cited by 32
Self-citationOhtawa, M., Masuda, N., Akasaka, I., Nakashima, A., Ochiai, K., & Moriyasu, M. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00901.x · Cited by 18
Cited by
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1749-4 · Cited by 334
Shah, F., Leung, L., Barton, H. A., Will, Y., Rodrigues, A. D., Greene, N., & Aleo, M. D. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv152 · Cited by 148
Yoshikado, T., Toshimoto, K., Nakada, T., Ikejiri, K., Kusuhara, H., Maeda, K., & Sugiyama, Y. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074823 · Cited by 54
Self-citationDe Bruyn, T., Ufuk, A., Cantrill, C., Kosa, R. E., Bi, Y.-A., Niosi, M., Modi, S., Rodrigues, A. D., Tremaine, L. M., Varma, M. V. S., et al. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.081315 · Cited by 53
Metadata
- Authors
- Shitara, Y., Maeda, K., Ikejiri, K., Yoshida, K., Horie, T., & Sugiyama, Y.
- Venue
- Biopharmaceutics & Drug Disposition
- Publisher
- Wiley
- Published
- 2013-01
- Volume
- 34
- Issue
- 1
- Pages
- 45-78
- ISSN
- 0142-2782 (ISSN-L)
- 1099-081X
- OpenAlex
- W1868407335
- Cited by
- 418
- References
- 151
- FWCI
- 12.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.